Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers

Aung Ko Win, Susan Parry, Bryan Parry, Matthew F. Kalady, Finlay A. Macrae, Dennis J. Ahnen, Graeme P. Young, Lara Lipton, Ingrid Winship, Alex Boussioutas, Joanne P. Young, Daniel D. Buchanan, Julie Arnold, Loïc Le Marchand, Polly A. Newcomb, Robert W. Haile, Noralane Morey Lindor, Steven Gallinger, John L. Hopper, Mark A. Jenkins

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background: Despite regular surveillance colonoscopy, the metachronous colorectal cancer risk for mismatch repair (MMR) gene mutation carriers after segmental resection for colon cancer is high and total or subtotal colectomy is the preferred option. However, if the index cancer is in the rectum, management decisions are complicated by considerations of impaired bowel function. We aimed to estimate the risk of metachronous colon cancer for MMR gene mutation carriers who underwent a proctectomy for index rectal cancer. Methods: This retrospective cohort study comprised 79 carriers of germline mutation in a MMR gene (18 MLH1, 55 MSH2, 4 MSH6, and 2 PMS2) from the Colon Cancer Family Registry who had had a proctectomy for index rectal cancer. Cumulative risks of metachronous colon cancer were calculated using the Kaplan-Meier method. Results: During median 9 years (range 1-32 years) of observation since the first diagnosis of rectal cancer, 21 carriers (27 %) were diagnosed with metachronous colon cancer (incidence 24.25, 95 % confidence interval [CI] 15.81-37.19 per 1,000 person-years). Cumulative risk of metachronous colon cancer was 19 % (95 % CI 9-31 %) at 10 years, 47 (95 % CI 31-68 %) at 20 years, and 69 % (95 % CI 45-89 %) at 30 years after surgical resection. The frequency of surveillance colonoscopy was 1 colonoscopy per 1.16 years (95 % CI 1.01-1.31 years). The AJCC stages of the metachronous cancers, where available, were 72 % stage I, 22 % stage II, and 6 % stage III. Conclusions: Given the high metachronous colon cancer risk for MMR gene mutation carriers diagnosed with an index rectal cancer, proctocolectomy may need to be considered.

Original languageEnglish (US)
Pages (from-to)1829-1836
Number of pages8
JournalAnnals of Surgical Oncology
Volume20
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

DNA Mismatch Repair
Rectal Neoplasms
Colonic Neoplasms
Mutation
Confidence Intervals
Genes
Colonoscopy
Colectomy
Germ-Line Mutation
Rectum
Registries
Colorectal Neoplasms
Neoplasms
Cohort Studies
Retrospective Studies
Observation
Incidence

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Win, A. K., Parry, S., Parry, B., Kalady, M. F., Macrae, F. A., Ahnen, D. J., ... Jenkins, M. A. (2013). Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. Annals of Surgical Oncology, 20(6), 1829-1836. https://doi.org/10.1245/s10434-012-2858-5

Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. / Win, Aung Ko; Parry, Susan; Parry, Bryan; Kalady, Matthew F.; Macrae, Finlay A.; Ahnen, Dennis J.; Young, Graeme P.; Lipton, Lara; Winship, Ingrid; Boussioutas, Alex; Young, Joanne P.; Buchanan, Daniel D.; Arnold, Julie; Le Marchand, Loïc; Newcomb, Polly A.; Haile, Robert W.; Lindor, Noralane Morey; Gallinger, Steven; Hopper, John L.; Jenkins, Mark A.

In: Annals of Surgical Oncology, Vol. 20, No. 6, 06.2013, p. 1829-1836.

Research output: Contribution to journalArticle

Win, AK, Parry, S, Parry, B, Kalady, MF, Macrae, FA, Ahnen, DJ, Young, GP, Lipton, L, Winship, I, Boussioutas, A, Young, JP, Buchanan, DD, Arnold, J, Le Marchand, L, Newcomb, PA, Haile, RW, Lindor, NM, Gallinger, S, Hopper, JL & Jenkins, MA 2013, 'Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers', Annals of Surgical Oncology, vol. 20, no. 6, pp. 1829-1836. https://doi.org/10.1245/s10434-012-2858-5
Win, Aung Ko ; Parry, Susan ; Parry, Bryan ; Kalady, Matthew F. ; Macrae, Finlay A. ; Ahnen, Dennis J. ; Young, Graeme P. ; Lipton, Lara ; Winship, Ingrid ; Boussioutas, Alex ; Young, Joanne P. ; Buchanan, Daniel D. ; Arnold, Julie ; Le Marchand, Loïc ; Newcomb, Polly A. ; Haile, Robert W. ; Lindor, Noralane Morey ; Gallinger, Steven ; Hopper, John L. ; Jenkins, Mark A. / Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. In: Annals of Surgical Oncology. 2013 ; Vol. 20, No. 6. pp. 1829-1836.
@article{f31adeb501314f7ebb4c96e0dedf504c,
title = "Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers",
abstract = "Background: Despite regular surveillance colonoscopy, the metachronous colorectal cancer risk for mismatch repair (MMR) gene mutation carriers after segmental resection for colon cancer is high and total or subtotal colectomy is the preferred option. However, if the index cancer is in the rectum, management decisions are complicated by considerations of impaired bowel function. We aimed to estimate the risk of metachronous colon cancer for MMR gene mutation carriers who underwent a proctectomy for index rectal cancer. Methods: This retrospective cohort study comprised 79 carriers of germline mutation in a MMR gene (18 MLH1, 55 MSH2, 4 MSH6, and 2 PMS2) from the Colon Cancer Family Registry who had had a proctectomy for index rectal cancer. Cumulative risks of metachronous colon cancer were calculated using the Kaplan-Meier method. Results: During median 9 years (range 1-32 years) of observation since the first diagnosis of rectal cancer, 21 carriers (27 {\%}) were diagnosed with metachronous colon cancer (incidence 24.25, 95 {\%} confidence interval [CI] 15.81-37.19 per 1,000 person-years). Cumulative risk of metachronous colon cancer was 19 {\%} (95 {\%} CI 9-31 {\%}) at 10 years, 47 (95 {\%} CI 31-68 {\%}) at 20 years, and 69 {\%} (95 {\%} CI 45-89 {\%}) at 30 years after surgical resection. The frequency of surveillance colonoscopy was 1 colonoscopy per 1.16 years (95 {\%} CI 1.01-1.31 years). The AJCC stages of the metachronous cancers, where available, were 72 {\%} stage I, 22 {\%} stage II, and 6 {\%} stage III. Conclusions: Given the high metachronous colon cancer risk for MMR gene mutation carriers diagnosed with an index rectal cancer, proctocolectomy may need to be considered.",
author = "Win, {Aung Ko} and Susan Parry and Bryan Parry and Kalady, {Matthew F.} and Macrae, {Finlay A.} and Ahnen, {Dennis J.} and Young, {Graeme P.} and Lara Lipton and Ingrid Winship and Alex Boussioutas and Young, {Joanne P.} and Buchanan, {Daniel D.} and Julie Arnold and {Le Marchand}, Lo{\"i}c and Newcomb, {Polly A.} and Haile, {Robert W.} and Lindor, {Noralane Morey} and Steven Gallinger and Hopper, {John L.} and Jenkins, {Mark A.}",
year = "2013",
month = "6",
doi = "10.1245/s10434-012-2858-5",
language = "English (US)",
volume = "20",
pages = "1829--1836",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers

AU - Win, Aung Ko

AU - Parry, Susan

AU - Parry, Bryan

AU - Kalady, Matthew F.

AU - Macrae, Finlay A.

AU - Ahnen, Dennis J.

AU - Young, Graeme P.

AU - Lipton, Lara

AU - Winship, Ingrid

AU - Boussioutas, Alex

AU - Young, Joanne P.

AU - Buchanan, Daniel D.

AU - Arnold, Julie

AU - Le Marchand, Loïc

AU - Newcomb, Polly A.

AU - Haile, Robert W.

AU - Lindor, Noralane Morey

AU - Gallinger, Steven

AU - Hopper, John L.

AU - Jenkins, Mark A.

PY - 2013/6

Y1 - 2013/6

N2 - Background: Despite regular surveillance colonoscopy, the metachronous colorectal cancer risk for mismatch repair (MMR) gene mutation carriers after segmental resection for colon cancer is high and total or subtotal colectomy is the preferred option. However, if the index cancer is in the rectum, management decisions are complicated by considerations of impaired bowel function. We aimed to estimate the risk of metachronous colon cancer for MMR gene mutation carriers who underwent a proctectomy for index rectal cancer. Methods: This retrospective cohort study comprised 79 carriers of germline mutation in a MMR gene (18 MLH1, 55 MSH2, 4 MSH6, and 2 PMS2) from the Colon Cancer Family Registry who had had a proctectomy for index rectal cancer. Cumulative risks of metachronous colon cancer were calculated using the Kaplan-Meier method. Results: During median 9 years (range 1-32 years) of observation since the first diagnosis of rectal cancer, 21 carriers (27 %) were diagnosed with metachronous colon cancer (incidence 24.25, 95 % confidence interval [CI] 15.81-37.19 per 1,000 person-years). Cumulative risk of metachronous colon cancer was 19 % (95 % CI 9-31 %) at 10 years, 47 (95 % CI 31-68 %) at 20 years, and 69 % (95 % CI 45-89 %) at 30 years after surgical resection. The frequency of surveillance colonoscopy was 1 colonoscopy per 1.16 years (95 % CI 1.01-1.31 years). The AJCC stages of the metachronous cancers, where available, were 72 % stage I, 22 % stage II, and 6 % stage III. Conclusions: Given the high metachronous colon cancer risk for MMR gene mutation carriers diagnosed with an index rectal cancer, proctocolectomy may need to be considered.

AB - Background: Despite regular surveillance colonoscopy, the metachronous colorectal cancer risk for mismatch repair (MMR) gene mutation carriers after segmental resection for colon cancer is high and total or subtotal colectomy is the preferred option. However, if the index cancer is in the rectum, management decisions are complicated by considerations of impaired bowel function. We aimed to estimate the risk of metachronous colon cancer for MMR gene mutation carriers who underwent a proctectomy for index rectal cancer. Methods: This retrospective cohort study comprised 79 carriers of germline mutation in a MMR gene (18 MLH1, 55 MSH2, 4 MSH6, and 2 PMS2) from the Colon Cancer Family Registry who had had a proctectomy for index rectal cancer. Cumulative risks of metachronous colon cancer were calculated using the Kaplan-Meier method. Results: During median 9 years (range 1-32 years) of observation since the first diagnosis of rectal cancer, 21 carriers (27 %) were diagnosed with metachronous colon cancer (incidence 24.25, 95 % confidence interval [CI] 15.81-37.19 per 1,000 person-years). Cumulative risk of metachronous colon cancer was 19 % (95 % CI 9-31 %) at 10 years, 47 (95 % CI 31-68 %) at 20 years, and 69 % (95 % CI 45-89 %) at 30 years after surgical resection. The frequency of surveillance colonoscopy was 1 colonoscopy per 1.16 years (95 % CI 1.01-1.31 years). The AJCC stages of the metachronous cancers, where available, were 72 % stage I, 22 % stage II, and 6 % stage III. Conclusions: Given the high metachronous colon cancer risk for MMR gene mutation carriers diagnosed with an index rectal cancer, proctocolectomy may need to be considered.

UR - http://www.scopus.com/inward/record.url?scp=84878234117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878234117&partnerID=8YFLogxK

U2 - 10.1245/s10434-012-2858-5

DO - 10.1245/s10434-012-2858-5

M3 - Article

C2 - 23358792

AN - SCOPUS:84878234117

VL - 20

SP - 1829

EP - 1836

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 6

ER -